Please login (Members) to view content or
(Nonmembers) this article.
Average: 5 (1 vote)
Online Exclusive Article

Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events

Kathleen Clifford
Amanda Copeland
Gregory Knutzen
Ellen Samuelson
Laurie Grove
Karen Schiavo
CJON 2018, 22(4), E103-E114 DOI: 10.1188/18.CJON.E103-E114

Background: Brentuximab vedotin (BV) is an antibody–drug conjugate that targets CD30-expressing cells.

Objectives: This article assesses the occurrence and management of the most frequent and clinically relevant BV-associated adverse events (AEs), with a focus on Hodgkin lymphoma and systemic anaplastic large cell lymphoma trials, and shares practical tips that may help decrease occurrence and severity.

Methods: Peer-reviewed literature was surveyed to collect safety data from sponsored clinical trials of BV and to compile associated management guidelines.

Findings: Peripheral neuropathy was the most common BV-associated AE across clinical trials. Other clinically relevant AEs included neutropenia, infection, and infusion-related reactions. Awareness of and preparedness for these common BV-associated AEs and other less common but significant AEs will help nurse clinicians and patients maximize the clinical benefit for patients receiving BV.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or